saplin

ICICI Prudential Nifty Pharma Index Fund

ICICI Prudential Nifty Pharma Index Fund (Direct, Growth): saplin Score 6.9/10 (Neutral) among 138 Index funds. 3Y return 22.9% a year vs 12.0% category median, expense ratio 0.51%. A small fund size hold this fund back. NAV ₹22.28 on 11 Nov 2026.

Loading the full analysis…

Questions about ICICI Prudential Nifty Pharma Index Fund

What is the expense ratio of ICICI Prudential Nifty Pharma Index Fund?

The Direct plan's total expense ratio is 0.51% a year, against a median of 0.54% for index funds. The Regular plan costs more because it pays a distributor's commission.

Who manages ICICI Prudential Nifty Pharma Index Fund?

Nishit Patel (since 14 Dec 2022); Ashwini Bharucha (since 18 Dec 2024); Venus Ahuja (since 1 Nov 2025).

What are the top holdings of ICICI Prudential Nifty Pharma Index Fund?

Sun Pharmaceutical Industries 18.60%, Divi's Laboratories 12.28%, Laurus Labs 9.26%, Dr. Reddy's Laboratories 8.15%, Cipla 7.67% of the portfolio, as of 31 Oct 2026.

What returns has ICICI Prudential Nifty Pharma Index Fund given?

1 year: 28.8% (category median 1.2%); 3 years: 22.9% a year (category median 12.0%). Past returns do not predict future ones.

How big is ICICI Prudential Nifty Pharma Index Fund?

About ₹151 cr (AMFI's average for the latest quarter).

How does ICICI Prudential Nifty Pharma Index Fund score?

6.9 out of 10 (Neutral) on the saplin Score, which rates a fund against its own category on returns, risk, consistency, cost and its manager. See the methodology for how it is worked out.

More on ICICI Prudential Nifty Pharma Index